Related Experiment Video
Updated: Jul 11, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Immunization for atherosclerosis
Kuang-Yuh Chyu1, Jan Nilsson, Prediman K Shah
1Division of Cardiology, Cedars Sinai Medical Center, Suite 5531, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
This review summarizes experimental findings that highlight the complex roles of the immune system in atherogenesis. Immune activation can have either proatherogenic or atheroprotective effects. Immune-modulation therapy via an active or passive immunization strategy aims to exploit the atheroprotective aspects of the immune system to modulate atherosclerosis. Several experimental studies have demonstrated that such an approach is feasible and effective, raising the tantalizing possibility that an atheroprotective vaccine can be developed for clinical testing. Several potential immunogens have been identified and tested for their atheroprotective efficacy with variable results. Although several questions such as choice of optimal antigens, choice of most effective adjuvants, the optimal route of administration, durability of effects, and safety remain to be answered, we believe that a vaccine-based approach to manage atherosclerotic cardiovascular disease is a potentially viable paradigm.
This review summarizes experimental findings that highlight the complex roles of the immune system in atherogenesis. Immune activation can have either proatherogenic or atheroprotective effects. Immune-modulation therapy via an active or passive immunization strategy aims to exploit the atheroprotective aspects of the immune system to modulate atherosclerosis. Several experimental studies have demonstrated that such an approach is feasible and effective, raising the tantalizing possibility that an atheroprotective vaccine can be developed for clinical testing. Several potential immunogens have been identified and tested for their atheroprotective efficacy with variable results. Although several questions such as choice of optimal antigens, choice of most effective adjuvants, the optimal route of administration, durability of effects, and safety remain to be answered, we believe that a vaccine-based approach to manage atherosclerotic cardiovascular disease is a potentially viable paradigm.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease IV: Preventive Measures
Rheumatic Heart Disease III: Medical Management
